Ann Clin Microbiol.  2024 Jun;27(2):131-141. 10.5145/ACM.2024.27.2.7.

Dengue fever: epidemiology, clinical manifestations, diagnosis, and therapeutic strategies

• Namirimu T
• Kim S

• KMID: 2557873
• DOI: http://doi.org/10.5145/ACM.2024.27.2.7

Abstract

Dengue, a mosquito-borne viral infection, is rapidly increasing worldwide and affects over half of the world’s population in at-risk areas. Factors such as globalization, urbanization, and climate change have fueled its rapid geographical expansion. Although no indigenous dengue cases have been identified in Korea, the number of imported dengue cases has increased from travel to endemic regions. In Korea, dengue diagnosis relies mainly on detecting antidengue antibodies or viral nucleic acids using real-time polymerase chain reaction. Although specific antiviral treatments for dengue are currently unavailable, promising progress has been made in developing antiviral agents that target viral replication. Single-dose tetravalent live-attenuated dengue vaccine candidates are currently being evaluated for their safety and efficacy. Innovative vector control methods, including Wolbachia-infected and genetically modified species of Aedes mosquitos, have demonstrated promising results. Owing to the limited therapeutic options, vector control strategies remain a primary focus for preventing transmission, alongside ongoing research on antiviral drugs and vaccine development. This review provides insight into dengue fever transmission, clinical manifestations, and diagnosis. Additionally, it covers current global control measures, emerging treatment options, and the status of vaccines in development.

Keyword

dengue fever; transmission; clinical manifestation; diagnosis; vaccines

Figure

• 

  Fig. 1. Dengue virus transmission cycle (illustration adapted from Gómez et al. [28]).

• 

  Fig. 2. The clinical course of dengue shows the three distinct phases (illustration reproduced from Yacoub et al. [23], with permission).

Reference

1. WHO. Dengue guidelines for diagnosis, treatment, prevention and control: new edition. Geneva: World Health Organization; 2009. .

2. Kraemer MU, Sinka ME, Duda KA, Mylne AQ, Shearer FM, Barker CM, et al. The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus. eLife 2015;4:e08347. .

3. Chen LH, Marti C, Diaz Perez C, Jackson BM, Simon AM, Lu M. Epidemiology and burden of dengue fever in the United States: a systematic review. J Travel Med 2023;30:taad127. .

4. Ferreira GL. Global dengue epidemiology trends. Rev Inst Med Trop Sao Paulo 2012;54:5-6. .

5. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature 2013;496:504-7. .

6. Gubler DJ. Dengue/dengue haemorrhagic fever: history and current status. In: Bock GR, Goode JA, eds. New treatment strategies for dengue and other flaviviral diseases: Novartis foundation symposium 277. Chichester; John Wiley & Sons, 2006:3-22. .

7. Gubler DJ. Dengue, urbanization and globalization: the unholy trinity of the 21st century. Trop Med Health 2011;39:S3-11. .

8. Murray NEA, Quam MB, Wilder-Smith A. Epidemiology of dengue: past, present and future prospects. Clin Epidemiol 2013;299-309. .

9. Messina JP, Brady OJ, Golding N, Kraemer MUG, Wint GRW, Ray SE, et al. The current and future global distribution and population at risk of dengue. Nat Microbiol 2019;4:1508-15. .

10. KDCA. Infectious diseases portal. https://dportal.kdca.go.kr/pot/is/inftnsds.do [Online] (last visited on 24 May 2024). .

11. Cho KH, Park SY, Lee WC, Lee MJ, Lee JB. International travel and exotic dengue fever in South Korea from 2006 to 2015. Jpn J Infect Dis 2018;71:378-81. .

12. Kim JS, Kang HJ, Lim A, Lee YJ, Lee DY, Han MG. Serotypes of imported dengue fever cases in South Korea, 2018-2020. Public Health Wkly Rep 2021;14:2366-73. .

13. Chung SM, Song JY, Kim W, Choi MJ, Jeon JH, Kang S, et al. Dengue-associated hemophagocytic lymphohistiocytosis in an adult: a case report and literature review. Medicine 2017;96:e6159. .

14. Park S, Ryu S, Jin K, Hwang E, Han S, Kim H, et al. Acute colitis associated with dengue fever in a renal transplant recipient. Transplant Proc 2008;40:2431-2. .

15. Song H, Jung BK, Cho J, Chang T, Huh S, Chai JY. Molecular identification of Anisakis larvae extracted by gastrointestinal endoscopy from health check-up patients in Korea. Korean J Parasitol 2019;57:207-211 .

16. Chang CY. Acute diverticulitis: a rare complication of dengue fever. Chonnam Med J 2021;57:158. .

17. Mason PW, McAda PC, Mason TL, Fournier MJ. Sequence of the dengue-1 virus genome in the region encoding the three structural proteins and the major nonstructural protein NS1. Virol 1987;161:262-7. .

18. Teixeira MdG, Barreto ML, Guerra Z. Epidemiologia e medidas de prevenção do dengue. Inf Epidemiol Sus 1999;8:5-33. .

19. Zahoor MK, Rasul A, Zahoor MA, Sarfraz I, Zulhussnain M, Rasool R, et al. Dengue fever: a general perspective. In: Falcón-Lezama JA, Betancourt-Cravioto M, Tapia-Conyer R, eds. Dengue fever: a resilient threat in the face of innovation. London; IntechOpen, 2019:1. .

20. Ferreira-de-Lima VH and Lima-Camara TN. Natural vertical transmission of dengue virus in Aedes aegypti and Aedes albopictus: a systematic review. Parasit Vectors 2018;11:1-8. .

21. Kulkarni R, Tiraki D, Wani D, Mishra AC, Arankalle VA. Risk of transfusion-associated dengue: screening of blood donors from Pune, western India. Transfusion 2019;59:458-62. .

22. Trejo I, Barnard M, Spencer JA, Keithley J, Martinez KM, Crooker I, et al. Changing temperature profiles and the risk of dengue outbreaks. PLoS Clim 2023;2:e0000115. .

23. Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nat Rev Dis Primers 2016;2:16055. .

24. Chouin-Carneiro T and dos Santos FB. Transmission of major arboviruses in Brazil: the role of Aedes aegypti and Aedes albopictus vectors. In: Shields VD, ed. Biological control of pest and vector insects. London; IntechOpen, 2017:2. .

25. Tjaden NB, Thomas SM, Fischer D, Beierkuhnlein C. Extrinsic incubation period of dengue: knowledge, backlog, and applications of temperature dependence. PLoS Negl Trop Dis 2013;7:e2207. .

26. Yoon IK, Getis A, Aldstadt J, Rothman AL, Tannitisupawong D, Koenraadt CJ, et al. Fine scale spatiotemporal clustering of dengue virus transmission in children and Aedes aegypti in rural Thai villages. PLoS Negl Trop Dis 2012;6:e1730. .

27. Li HH, Su MP, Wu SC, Tsou HH, Chang MC, Cheng YC, et al. Mechanical transmission of dengue virus by Aedes aegypti may influence disease transmission dynamics during outbreaks. eBioMedicine 2023;94:104723. .

28. Gómez M, Martinez D, Muñoz M, Ramírez JD. Aedes aegypti and Ae. albopictus microbiome/ virome: new strategies for controlling arboviral transmission? Parasit Vectors 2022;15:287. .

29. Kalayanarooj S. Clinical manifestations and management of dengue/DHF/DSS. Trop Med Health 2011;39:S83-7. .

30. Kala MP, St. John AL, Rathore AP. Dengue: update on clinically relevant therapeutic strategies and vaccines. Curr Treat Options Infect Dis 2023;15:27-52. .

31. Yacoub S, Wertheim H, Simmons CP, Screaton G, Wills B. Cardiovascular manifestations of the emerging dengue pandemic. Nat Rev Cardiol 2014;11:335-45. .

32. Kularatne SA and Dalugama C. Dengue infection: global importance, immunopathology and management. Clin Med 2022;22:9-13. .

33. Tejo AM, Hamasaki DT, Menezes LM, Ho YL. Severe dengue in the intensive care unit. J Intensive Med 2024;4:16-33. .

34. Wilder-Smith A and Schwartz E. Dengue in travelers. N Engl J Med 2005;353:924-32. .

35. Guzman MG, Jaenisch T, Gaczkowski R, Ty Hang VT, Sekaran SD, Kroeger A, et al. Multicountry evaluation of the sensitivity and specificity of two commercially-available NS1 ELISA assays for dengue diagnosis. PLoS Negl Trop Dis 2010;4:e811. .

36. Macêdo JV, Frias IA, Oliveira MD, Zanghelini F, Andrade CA. A systematic review and metaanalysis on the accuracy of rapid immunochromatographic tests for dengue diagnosis. Eur J Clin Microbiol Infect Dis 2022;41:1191-201. .

37. Clarke DH and Casals J. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg 1958;7:561-73. .

38. Simmons CP, Farrar JJ, van Vinh Chau N, Wills B. Dengue. N Engl J Med 2012;366:1423-32. .

39. Casenghi M, Kosack C, Li R, Bastard M, Ford N. NS1 antigen detecting assays for diagnosing acute dengue infection in people living in or returning from endemic countries. Cochrane Database Syst Rev 2014. .

40. Sang CT, Cuzzubbo AJ, Devine PL. Evaluation of a commercial capture enzyme-linked immunosorbent assay for detection of immunoglobulin M and G antibodies produced during dengue infection. Clin Diagn Lab Immunol 1998;5:7-10. .

41. Schwartz E, Mileguir F, Grossman Z, Mendelson E. Evaluation of ELISA-based serodiagnosis of dengue fever in travelers. J Clin Virol 2000;19:169-73. .

42. Park JH and Lee DW. Dengue fever in South Korea, 2006–2010. Emerg Infect Dis 2012;18:1525. .

43. Tayal A, Kabra SK, Lodha R. Management of dengue: an updated review. Indian J Pediatr 2023;90:168-77. .

44. Kaptein SJ, Goethals O, Kiemel D, Marchand A, Kesteleyn B, Bonfanti JF, et al. A panserotype dengue virus inhibitor targeting the NS3–NS4B interaction. Nature 2021;598:504-9. .

45. Low ZX, OuYong BM, Hassandarvish P, Poh CL, Ramanathan B. Antiviral activity of silymarin and baicalein against dengue virus. Sci Rep 2021;11:21221. .

46. Achee NL, Gould F, Perkins TA, Reiner Jr. RC, Morrison AC, Ritchie SA, et al. A critical assessment of vector control for dengue prevention. PLoS Negl Trop Dis 2015;9:e0003655. .

47. Jing Q and Wang M. Dengue epidemiology. Glob J Health Sci 2019;3:37-45. .

48. Ritchie SA and Johnson BJ. Advances in vector control science: rear-and-release strategies show promise… but don’t forget the basics. J Infect Dis 2017;215:S103-8. .

49. Fox T, Sguassero Y, Chaplin M, Rose W, Doum D, Arevalo-Rodriguez I, et al. Wolbachiacarrying Aedes mosquitoes for preventing dengue infection. Cochrane Database Syst Rev 2023. .

50. Moreira LA, Iturbe-Ormaetxe I, Jeffery JA, Lu G, Pyke AT, Hedges LM, et al. A Wolbachia symbiont in Aedes aegypti limits infection with dengue, Chikungunya, and Plasmodium. Cell 2009;139:1268-78. .

51. Lambrechts L, Ferguson NM, Harris E, Holmes EC, McGraw EA, O'Neill SL, et al. Assessing the epidemiological effect of Wolbachia for dengue control. Lancet Infect Dis 2015;15:862-6. .

52. Zhang H and Lui R. Releasing Wolbachia-infected Aedes aegypti to prevent the spread of dengue virus: a mathematical study. Infect Dis Model 2020;5:142-60. .

53. Ross PA, Robinson KL, Yang Q, Callahan AG, Schmidt TL, Axford JK, et al. A decade of stability for wMel Wolbachia in natural Aedes aegypti populations. PLoS Pathog 2022;18:e1010256. .

54. Hoffmann AA, Montgomery BL, Popovici J, Iturbe-Ormaetxe I, Johnson PH, Muzzi F, et al. Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature 2011;476:454-7. .

55. Walker T, Johnson P, Moreira L, Iturbe-Ormaetxe I, Frentiu F, McMeniman C, et al. The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations. Nature 2011;476:450-3. .

56. Ritchie S. Rear and release: a new paradigm for dengue control. Austral Entomol 2014;53:3637. .

57. Lenharo M. Dengue is spreading. Can new vaccines and antivirals halt its rise? Nature 2023;623:470. .

58. Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015;373:1195-206. .

59. Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, O'Brien K, Vannice K, et al. Deliberations of the Strategic Advisory Group of Experts on immunization on the use of CYD-TDV dengue vaccine. Lancet Infect Dis 2019;19:e31-8. .

60. López-Medina E, Biswal S, Saez-Llorens X, Borja-Tabora C, Bravo L, Sirivichayakul C, et al. Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents 2 years after vaccination. J Infect Dis 2022;225:1521-32. .

61. Malavige GN, Sjö P, Singh K, Piedagnel JM, Mowbray C, Estani S, et al. Facing the escalating burden of dengue: challenges and perspectives. PLoS Glob Public Health 2023;3:e0002598. .

62. Kallás EG, Cintra MA, Moreira JA, Patiño EG, Braga PE, Tenório JC, et al. Live, attenuated, tetravalent Butantan–Dengue vaccine in children and adults. N Engl J Med 2024;390:397-408. .

63. Gunale B, Farinola N, Yeolekar L, Shrivastava S, Girgis H, Poonawalla CS, et al. A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults. Vaccine 2023;41:5614-21. .

64. Wilder-Smith A. Dengue vaccine development: challenges and prospects. Curr Opin Infect Dis 2022;35:390-6. .

65. Thisyakorn U and Thisyakorn C. Latest developments and future directions in dengue vaccines. Ther Adv Vaccines Immunother 2014;2:3-9. .

66. Young E, Yount B, Pantoja P, Henein S, Meganck RM, McBride J, et al. A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotypespecific immunity. Nat Commun 2023;14:1371. .

67. Sakinah S, Priya SP, Mok PL, Munisvaradass R, Teh SW, Sun Z, et al. Stem cell therapy in dengue virus-infected BALB/C mice improves hepatic injury. Front Cell Dev Biol 2021;9:637270. .

68. Rodriguez-Manzano J, Chia PY, Yeo TW, Holmes A, Georgiou P, Yacoub S. Improving dengue diagnostics and management through innovative technology. Curr Infect Dis Rep 2018;20:1-8. .